ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Prognostic Implications of MDM2 and CDK4 Co-amplification in Liposarcoma: Insights from FISH analysis for Translational Oncology.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Atypical Spindle Cell/Pleomorphic Lipomatous Tumor with Atypical Imaging Features.Diagnostics (Basel, Switzerland) · 2026Article
- Review
- Primary liposarcoma of the pericardium: report of a rare case with clinicopathological features and imaging insights.BMC cardiovascular disorders · 2026Article
- Molecular and Immune Mechanisms Governing Cancer Metastasis, Including Dormancy, Microenvironmental Niches, and Tumor-Specific Programs.International journal of molecular sciences · 2026Review
- Angiomatoid fibrous histiocytoma with CDK4 and MDM2 expression misdiagnosed as dedifferentiated liposarcoma: The first case report and literature review.SAGE open medical case reports · 2026Article
- Long-term survival with eribulin in an elderly patient with inoperable retroperitoneal well-differentiated liposarcoma: a case report and literature review.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeMDM2 and CDK4 amplifications are well-established diagnostic markers in liposarcoma, but the clinical relevance of their co-amplification remains underexplored. This study evaluates their amplification characteristics and combined prognostic impact to inform risk stratification and patient management.
methodsFluorescence in situ hybridisation (FISH) was performed on formalin-fixed paraffin-embedded samples of liposarcoma or benign lipomatous tumours (≥ 10 cm) histologically diagnosed at Hospital Pakar Universiti Sains Malaysia. Recurrence-free (RFS) and metastasis-free survival (MFS) across amplifications were determined using Kaplan-Meier. Recurrence associations with clinicopathological variables were examined using Cox regression.
resultsAmong 86 cases, 27% were liposarcoma and 73% were benign tumours by FISH. Co-amplification (13%) was observed in all dedifferentiated liposarcoma (DDLS) and half of atypical lipomatous tumour/well-differentiated liposarcoma (ALT/WDLS) cases. MDM2 amplification without CDK4 (6%) was seen in ALT. Myxoid liposarcoma, pleomorphic liposarcoma, and benign tumours showed no amplification (81%). DDLS had higher MDM2 and CDK4 amplification ratios (4.4 and 2.8, respectively) than ALT/WDLS (2.9 and 2.6, respectively), with MDM2 consistently exceeding CDK4. Co-amplification associated with the shortest median RFS (34 months; p = 0.002) and MFS (83 months; p = 0.003). Surgery with chemotherapy (p = 0.042; HR = 26.50) associated with recurrence, while MDM2/CDK4 amplification was not an independent prognostic factor.
conclusionMDM2 amplification was more consistent and quantitatively higher than CDK4, supporting its central role in tumourigenesis. While MDM2/CDK4 co-amplification was associated with poorer outcomes, it lacked independent prognostic value, reflecting the potential influence of other clinical variables. Nevertheless, co-amplification may hold clinical relevance in identifying high-risk liposarcoma subgroups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.